One is the enhancement of estrogen binding to the ESR1 which, acutely, may stimulate estrogen-sensitive cancers but chronically and at higher CAP dosages would likely downregulate ESR1 expression, thus producing a tamoxifen-like effect. The gene discussed is ESR1; the disease is cancer.